Bridgeway Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Bridgeway Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,265	Closed	-$72.8K	–	1428
2023 Q1	$72.8K	Hold	10,265	–	–	﹤0.01%	1279
2022 Q4	$65.9K	Hold	10,265	–	–	﹤0.01%	1274
2022 Q3	$150K	Hold	10,265	–	–	﹤0.01%	1197
2022 Q2	$185K	Hold	10,265	–	–	﹤0.01%	1107
2022 Q1	$306K	Buy	+10,265	New	+$328K	0.01%	1074
2021 Q3	–	Sell	-5,265	Closed	-$604K	–	1329
2021 Q2	$604K	Sell	5,265 -4,750	-47%	-$464K	0.01%	1016
2021 Q1	$1.04M	Sell	10,015 -2,750	-22%	-$261K	0.02%	848
2020 Q4	$610K	Hold	12,765	–	–	0.01%	878
2020 Q3	$355K	Buy	12,765 +5,000	+64%	+$143K	0.01%	1004
2020 Q2	$297K	Sell	7,765 -3,750	-33%	-$194K	0.01%	1042
2020 Q1	$564K	Hold	11,515	–	–	0.01%	728
2019 Q4	$518K	Sell	11,515 -2,000	-15%	-$72.2K	0.01%	978
2019 Q3	$568K	Buy	13,515 +5,000	+59%	+$197K	0.01%	904
2019 Q2	$424K	Sell	8,515 -1,235	-13%	-$103K	0.01%	1020
2019 Q1	$770K	Hold	9,750	–	–	0.01%	858
2018 Q4	$269K	Sell	9,750 -5,250	-35%	-$189K	﹤0.01%	1160
2018 Q3	$750K	Hold	15,000	–	–	0.01%	1012
2018 Q2	$765K	Buy	15,000 +9,250	+161%	+$456K	0.01%	985
2018 Q1	$242K	Sell	5,750 -1,500	-21%	-$99.1K	﹤0.01%	1245
2017 Q4	$674K	Hold	7,250	–	–	0.01%	996
2017 Q3	$1.09M	Hold	7,250	–	–	0.01%	812
2017 Q2	$754K	Hold	7,250	–	–	0.01%	944
2017 Q1	$866K	Buy	7,250 +2,250	+45%	+$260K	0.01%	864
2016 Q4	$705K	Hold	5,000	–	–	0.01%	945
2016 Q3	$504K	Hold	5,000	–	–	0.01%	1102
2016 Q2	$356K	Buy	+5,000	New	+$467K	0.01%	1177

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's IMDX Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Insight Molecular Diagnostics (IMDX) in Q2 2023, closing a stake of 10,265 shares — an estimated $72.8K sold.

Bridgeway Capital Management first reported a position in IMDX in Q2 2016 and held it in 26 quarters. The position peaked at $1.09M in Q3 2017. 47 funds tracked by Wall St. Rank hold IMDX as of Q2 2023.

Bridgeway Capital Management reported no remaining Insight Molecular Diagnostics position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 10,265 Insight Molecular Diagnostics shares in Q2 2023, an estimated $72.8K.
Bridgeway Capital Management first reported a position in Insight Molecular Diagnostics in Q2 2016 and held it in 26 quarters.
Bridgeway Capital Management's Insight Molecular Diagnostics position peaked at $1.09M in Q3 2017.
47 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.